Clinical Trials Browser

Phase 2 × Biliary Tract Neoplasms × Hydroxychloroquine × Clear all

NCT04566133 2023-08-21

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Phase 2 Terminated

2 enrolled 9 charts

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma